High Purity>99% Raw Lyophilized Peptides Ss-31 Selank Mt2 Dsip Epithalon Adipotide Sema Tirze Semax Reta Powder
TDS 35 Inquiries
129954-34-3
Pharma Grade / Research Grade
99%
GUANGZHOU
HF
5mg/vial
2026-08-08
peptides
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceSelank is a synthetic derivative of the tetrapeptide tuftsin that contains a proline-glycine-proline sequence at the C-terminus and has anxiolytic and anti-inflammatory activities. It increases the amplitude and discharge rate of inhibitory postsynaptic currents of neurons in the rat hippocampal CA1 region when used at a concentration of 1 μM. It decreases the level of affective responses and the number of erroneous escape attempts in rats in an acute stress situation, increases orientational-investigative responses of rats in an unfamiliar situation, and reduces the time mice spend immobile in the forced swim test. It increases locomotor activity of high-anxiety Balb/c, but not C57Bl/6, mice in the open field test. Selank (0.01 mg/kg) decreases verticalization induced by apomorphine in mice. It also decreases expression of the inflammation-related genesIl2rgandXcr1in mouse spleen after 90 minutes when administered at a dose of 100 μg/kg.
SELANK Synthetic is a single, non-glycosylated polypeptide chain containing 7 amino acids, having a molecular mass of 751.89 Dalton and a Molecular formula of C33H57N11O9.CertificatesBasic Info-
Product Name:
Selank peptide
Other Name:Selank peptide;SelankAcetate;PL14736;L-threonyl-L-lysyl-L-prolyl-L-arginyl-L-prolylglycyl-L-proline;L-THREONYL-L-LYSYL-L-PROLYL-L-ARGINYL-L-PROLYLGLYCYL-L-PROLINE; MONOACETATE;H-Thr-Lys-Pro-Arg-Pro-Gly-Pro-OH;SLANK;Selank peptid
CAS No.:129954-34-3
Molecular Formula:C33H57N11O9
InChIKeys:JTDTXGMXNXBGBZ-YVHUGQOKSA-N
Molecular Weight:751.87
Exact Mass:751.43407244
EC Number:232-660-2
UNII:TS9JR8EP1G
Categories:
Characteristics-
Density:
1.53±0.1 g/cm3(Predicted)
Melting Point:134-136 °C
PKA:3.43±0.20(Predicted)
Research-
Class:
Mitochondria-targeted tetrapeptide (Szeto-Schiller peptide)
Status:FDA-approved (Forzinity) — Accelerated Approval 2025
Mechanism:A cell-permeable, synthetic tetrapeptide (D-Arg-Dmt-Lys-Phe-NH₂) that selectively concentrates in the inner mitochondrial membrane and reversibly binds to cardiolipin, a phospholipid essential for electron transport chain (ETC) function. By stabilizing cardiolipin, SS-31 restores mitochondrial bioenergetics, reduces cytochrome c peroxidase activity, and prevents oxidative damage in cells with impaired mitochondrial function.
Activity note:SS-31 does not act via traditional receptor agonism. It binds cardiolipin with high selectivity in the inner mitochondrial membrane. Functional EC₅₀ values are context-dependent (cell type, stress model). Key electrophysiology studies report mitochondrial membrane potential restoration at nanomolar concentrations.
Source:Szeto HH, et al. AAPS J. 2006;8(2):E277-E283. Birk AV, et al. J Am Soc Nephrol. 2014;25(6):1157-1169.DOI
Clinical Development:FDA:Forzinity (approved 2025-09-19)
References-
ChEMBL:DrugBank:KEGG DRUG:PubChem:Literature:
FDA: Forzinity (NDA 215244) — Accelerated Approval 2025; Genetics in Medicine: TAZPOWER Phase 2/3 results (Thompson et al. 2020); Drugs: Elamipretide First Approval (Springer 2025)
Disclaimer:Elamipretide (Forzinity) is FDA-approved under accelerated approval for Barth syndrome. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
peptides
-
Location:
No. 85, Qingnian Road, Hongqiao District, Tianjin
-
Total Annual Revenue:
$5 million-$10 million
-
Total Employees:
51-100
-
Year of Establishment:
2026
-
-
Inquiry History35 Inquiries
Country Product Purchase Quantity Date Posted
United States
Selank 99% Purity 129954-34-3
1 G Jan 23, 2026
Greece
selank
10 MG May 20, 2026
United States
N acetyl selank
500 MG Apr 30, 2026
United States
Selank
100 MG Apr 24, 2026
Italy
Nacetyl selank
1 MT Apr 22, 2026
Oman
Selank
1 G Mar 4, 2026
United States
Selank
30 40' Fcl Oct 14, 2025
United States
selank
30 MG May 25, 2026
Brazil
Selank
10 MT Apr 7, 2026
United States
selank
1 G Mar 13, 2026
United States
Selank
1 G Mar 9, 2026
United Kingdom
Selank
1 G Dec 22, 2025
United States
Selank
20 MG Nov 10, 2025
United States
NA-Selank Amidate
10 MG Sep 18, 2025
United Kingdom
Selank
100 MG Jul 15, 2025
United States
N-Acetyl Selank Amidate
1 KG Jan 9, 2025
United States
Selank
10 Mar 29, 2024
Poland
Selank
10 G Feb 18, 2024
United States
Selank
1 G Jan 27, 2024
United States
selank
100 MG Jul 7, 2026 Post an enquiry for this product
